Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence

Rebecca G. Rogers, Gloria Bachmann, Harriette Scarpero, Zhanna Jumadilova, Franklin Sun, Jon D. Morrow, Zhonghong Guan, Tamara Bavendam

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Objective: To assess the effects of tolterodine extended release (ER) on patient-reported outcomes (PROs) in sexually active women with overactive bladder (OAB) and urgency urinary incontinence (UUI). Research design and methods: This multicenter, double-blind, placebo controlled trial included 411 women aged ≥18 years reporting OAB symptoms for ≥3 months; ≥8 micturitions per 24 hours (including ≥0.6 UUI episodes and ≥3 OAB micturitions) in 5-day bladder diaries at baseline, and being in a sexually active relationship for ≥6 months. Subjects randomized to placebo or tolterodine ER completed validated OABor incontinence-specific questionnaires, including the Patient Perception of Bladder Condition (PPBC), Overactive Bladder Questionnaire (OAB-q), Urgency Perception Scale (UPS), and the Incontinence Impact Questionnaire (IIQ) at baseline and week 12, as well as the Perception of Treatment Benefit and Treatment Satisfaction questions at week 12. This study is registered with ClinicalTrials.gov (identifier: NCT00143481) Results: The mean age of enrolled women was approximately 48 years. Compared with placebo, the tolterodine ER group reported significant baseline to week 12 improvements in PPBC responses (p = 0.0048); OAB-q Symptom Bother, total Health-Related Quality of Life (HRQL), and HRQL domain scores (all p<0.05); IIQ Emotional Health domain scores (p<0.05); proportions of subjects reporting treatment benefit (79 vs. 54%; p<0.0001) and satisfaction (78 vs. 59%; p<0.0001). Improvements on the UPS were not significantly different. Conclusions: Tolterodine ER treatment was associated with improvements in multiple OAB- and incontinence-specific PROs in a sexually active, relatively young, and racially diverse population of women. The findings provide clinicians with new insights into the impact of OAB and its treatment on HRQL in this population, which has been underrepresented in previous OAB studies. Study limitations include a potential underestimation of the impact of OAB symptoms resulting from the exclusion of women who may not be sexually active because of their urinary symptoms.

Original languageEnglish (US)
Pages (from-to)2159-2165
Number of pages7
JournalCurrent Medical Research and Opinion
Volume25
Issue number9
DOIs
StatePublished - Sep 2009

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Keywords

  • Overactive bladder
  • Patient-reported outcomes
  • Sexual health
  • Urgency urinary incontinence
  • Women

Fingerprint

Dive into the research topics of 'Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence'. Together they form a unique fingerprint.

Cite this